| A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (NCT07608757) | Caliway Biopharmaceuticals Co., Ltd. | 2027-02-01 |
| A Study to Evaluate the Maintenance of Efficacy and Long-term Safety of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1) (NCT07733947) | Caliway Biopharmaceuticals Co., Ltd. | 2026-12-01 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat ( SUPREME-02 ) (NCT07526974) | Caliway Biopharmaceuticals Co., Ltd. | 2026-10-01 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat (NCT07140939) | Caliway Biopharmaceuticals Co., Ltd. | 2026-07-01 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (NCT07608770) | Caliway Biopharmaceuticals Co., Ltd. | 2026-06-01 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 Compared to Placebo in Participants With Dercum's Disease Lipomas (NCT06303570) | Caliway Biopharmaceuticals Co., Ltd. | 2024-11-27 |
| A Phase 2b Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat. (NCT06005441) | Caliway Biopharmaceuticals Co., Ltd. | 2023-11-10 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Abdominal Subcutaneous Fat (NCT05736107) | Caliway Biopharmaceuticals Co., Ltd. | 2023-05-30 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 2) (NCT05836779) | Caliway Biopharmaceuticals Co., Ltd. | 2023-05-10 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1) (NCT05632926) | Caliway Biopharmaceuticals Co., Ltd. | 2023-01-09 |
| A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas (NCT05387733) | Caliway Biopharmaceuticals Co., Ltd. | 2022-10-03 |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 2) (NCT04897412) | Caliway Biopharmaceuticals Co., Ltd. | 2022-02-14 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of CBL-514 Injection for Reducing Subcutaneous Fat (Stage 1) (NCT04575467) | Caliway Biopharmaceuticals Co., Ltd. | 2020-12-09 |
| A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of CBL-514 Injection for Reducing Convexity or Fullness of Abdominal Subcutaneous Fat (NCT04698642) | Caliway Biopharmaceuticals Co., Ltd. | 2020-02-03 |
| A Phase 1 Study to Evaluate the Safety and Tolerability of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers (NCT04699669) | Caliway Biopharmaceuticals Co., Ltd. | 2018-11-27 |